Products in Pipeline
|R&D||Preclinical||Phase 1||Phase 2||Phase 3|
(Multivalent Antibacterial Vaccine)
(Multivalent Antibacterial Monoclonal Antibodies)
Immunethep has developed the Paragon Novel Vaccine (PNV), a breakthrough vaccine providing effective protection against bacterial infections caused by 5 different bacteria: Staphylococcus aureus, Streptococcus pneumoniae, Klebsiella pneumoniae, Escherichia coli, and Streptococcus agalactiae (GBS).
PNV works by neutralizing an extracellular form of bacterial GAPDH, without blocking the human GAPDH. This will enable the host immune system to fight the infection and eliminate the bacteria.
Preclinical trials performed on animal models have demonstrated high levels of efficacy against all 5 bacteria with a strong safety profile.
PNV is a peptide-based immunotherapy that is stable at high temperatures and it is not freezing sensitive.
Once on the market, PNV will become the world’s first vaccine preventing multiple bacterial infections for all its invasive serotypes, including multi-resistant strains.
Immunethep is developing a therapeutic immunotherapy based on monoclonal antibodies with the following characteristics:
- Monoclonal antibody (IgG1) targeting bacterial GAPDH;
- Treats infection from all invasive serotypes of multiple bacteria;
- Very low probability of inducing resistance;
- Microbiome friendly
Immunethep has focused on developing a vaccine capable of optimising lung-specific immunity against the different variants of the virus. This proof-of-concept takes advantage of the high homology between the SARS-CoV-2 strain and the rest of the SARS-CoV family. By using the inactivated whole virus as the target antigen, the vaccine maximises the number of B- and T-cell epitopes and thus the immunogenicity of the vaccine.
Additionally, by maximizing the number of viral epitopes present in the vaccine, it decreases the probability of point mutations that escape vaccine efficacy, thus ensuring protection against different variants. This is not the case with the currently available EU approved vaccines that target the Spike protein, whether using recombinant technology, adenovirus, or even DNA/RNA.
The vaccine developed by Immunethep is inhalable, promoting robust antiviral responses against this virus in the nasopharynx and in the lung, the route of entry into the body. This confers to SILBA the ideal characteristics not only to provide initial immunity to unvaccinated population, but also to be used as an immunity booster to vaccines already administered, as it has a high and unchanged response capacity to new variants of the virus.